Mgmt stance: Neutral — managing India regulatory changes via CuRe technology; international backlog cadence unchanged.
Q4 — Christopher Dendrinos
Topic: Southeast Asia offtake decision tree under 232
Key points:
Malaysia/Vietnam capacity: 7 GW total; 3.5 GW moving to U.S. as semi-finished; ~1.8–2 GW remains for fully finished modules.
Decision outcomes: (1) run full capacity end-to-end for U.S. if 232 outcome favorable; (2) add incremental U.S. finishing line; (3) potential shutdown.
Current risk: tariff implications make pricing unattractive; 232 clarity expected to enable appropriate risk allocation.
Mgmt stance: Neutral — waiting for 232 outcome to determine long-term contracting and capacity utilization.
Q5 — Philip Shen
Topic: 232 framework timing, perovskite pilot line details
Key points:
232 framework: proposing $0.01/watt on cell or module, or minimum import price (~$0.38/watt); positive feedback from administration.
Timing: resolution expected by end of Q2 2025, but could slip to early Q3; confidence based on current communications.
Perovskite pilot line: 1 GW full-size Series 6 line in 2027; cost will be higher (sub-HVM scale); two paths (single-junction or tandem) under evaluation.
Priority: validate perovskite durability and bankability in field before tackling tandem complexity.
Mgmt stance: Bullish on 232 framework feedback; cautious on perovskite cost at launch, but optimistic about field validation path.
Q&A Batch (6-10 of 10)
Q6 — Mark Widmar
Topic: Demand and pricing uncertainty pending tariff communication
Key points:
Customers are waiting for multiple gigawatts of volume; outcome of tariff communication will impact volume and speed.
Current price negotiations reflect a midpoint expectation; if outcome is lower, ASP may face pressure; if higher, ASP may have upside.
Bid-ask spread in the market is driven by uncertainty around the tariff outcome.
Mgmt stance: Neutral — demand exists but pricing and booking pace depend entirely on the communicated tariff result.
Q7 — Colin Rusch
Topic: Series 6 to Series 7 (CuRe) technical transition and domestic capacity impact
Key points:
Series 6 to Series 7 is primarily a form factor change, not a major technical challenge; key change is moving front contact buffer deposition to glass suppliers for Series 7.
New tools for CuRe are first-of-kind, designed for Series 6 size; need seasoning for different form factors.
South Carolina facility will produce semi-finished Series 6 product with domestic content, enabling customers to blend with Ohio product for domestic content bonus (ITC value of $0.15–$0.20+ per project).
Mgmt stance: Bullish — technical transition is manageable, and new domestic capacity creates pricing competitiveness and customer value via ITC bonus.
Q8 — Praneeth Satish
Topic: India capacity allocation (U.S. vs. India) and bookings breakdown
Key points:
India demand is strong; 1 GW sold last quarter with highest gross margin (excluding 45X benefits). Changeover from fixed tilt to tracker product is inefficient.
Plan to keep running India product through H1; Q3 may see softness, Q4 stronger. Tariff environment uncertain after 122 expires end of July; 301s unknown.
Bringing 10s to low 100 MW of WIP from India to finish in U.S. in H1. Bookings: 1.7 GW total, 0.9 GW U.S., 0.8 GW India.
Mgmt stance: Cautious — focusing on India demand for now, but U.S. imports are limited and contingent on long-term tariff clarity.
Q9 — Maheep Mandloi
Topic: H1 vs. H2 EBITDA and volume cadence
Key points:
EBITDA is 36% in H1, but volumes are 44% in H1. Imbalance driven by India volumes: strong Q1, dropping in Q2/Q3, potentially picking up in Q4.
Mgmt stance: Neutral — the cadence is explained by India shipment timing, as per guidance.
Q10 — Joseph Osha
Topic: South Carolina capacity composition (3.5 GW) and perovskite pilot line
Key points:
South Carolina 3.5 GW is CuRe (CadTel) product, not perovskite; substrate glass with deposition shipped from Vietnam/Malaysia to be finished in U.S.
Perovskite pilot line (up to 1 GW) will be in Perrysburg, using existing facility and back-end tools; IP acquired from Oxford enhances existing IP.
Of original 7 GW in Malaysia/Vietnam, 3.5 GW front-end used for South Carolina; remaining 3.5 GW tools partly go to Perrysburg perovskite line.
2027 production midpoint unchanged at ~19.7 GW (from February deck).
On TOPCon patent: all TOPCon manufacturers selling into U.S. infringe FSLR IP; willing to license to Tesla at fair value, as done with Talen.
Mgmt stance: Bullish on capacity plan and IP position — production guidance unchanged; open to licensing TOPCon IP, but infringement is expected unless product is redesigned.